Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.
Am J Ophthalmol. 2011 Apr;151(4):714-718.e1. doi: 10.1016/j.ajo.2010.10.026. Epub 2011 Jan 22.
To compare treatment outcomes of intralesional triamcinolone acetonide (TA) injection with incision and curettage (I&C) for primary chalazia.
Prospective, randomized clinical trial.
Institutional.
Ninety-four patients with primary chalazia after failed conservative treatment were randomized to either intralesional TA injection (4 mg) or I&C performed under local anesthesia. All patients underwent comprehensive eye examinations that included digital photography of the lesion. Complete resolution was defined as lesion regression of 95% to 100%. Treatment was considered a failure if no resolution was achieved after the first attempted I&C or TA injection.
Lesion resolution measured as 95% to 100% regression.
Ninety-four patients participated in the study: 42 underwent I&C and 52 underwent TA injection as the first treatment. Complete resolution was achieved in 33 (79%) of 42 patients in the I&C group and in 42 (81%) of 52 patients in the TA group (P=.8, chi-square analysis). The average time to resolution in the TA group was 5 days, with most patients (48/52; 92%) having received a single injection and 4 (8%) of 52 patients having received 2 injections. TA precipitates were detected in 6 (11.5%) of 52 patients and resolved spontaneously. There were no complications, such as eyelid depigmentation, increased intraocular pressure, or any loss of vision, in either group.
Intralesional TA injection is as effective as I&C in primary chalazia. Injection may be considered as an alternative first-line treatment in cases where diagnosis is straightforward and no biopsy is required.
比较原发性霰粒肿经曲安奈德(TA)腔内注射与切开刮除(I&C)的治疗效果。
前瞻性、随机临床试验。
机构。
94 例经保守治疗失败的原发性霰粒肿患者,随机分为腔内 TA 注射(4mg)或局部麻醉下 I&C。所有患者均接受全面的眼部检查,包括病变的数字摄影。完全缓解定义为病变消退 95%~100%。如果第一次 I&C 或 TA 注射后未完全缓解,则视为治疗失败。
病变消退率为 95%~100%。
94 例患者参与了研究:42 例行 I&C,52 例行 TA 注射作为首次治疗。I&C 组中 33 例(79%)完全缓解,TA 组中 42 例(81%)完全缓解(P=.8,卡方分析)。TA 组的平均缓解时间为 5 天,大多数患者(48/52;92%)接受了单次注射,52 例患者中有 4 例(8%)接受了 2 次注射。在 52 例患者中,有 6 例(11.5%)检测到 TA 沉淀,且自行缓解。两组均无并发症,如眼睑色素减退、眼压升高或任何视力丧失。
腔内 TA 注射治疗原发性霰粒肿与 I&C 同样有效。对于诊断明确且无需活检的病例,注射可作为首选的一线治疗方法。